Effects of epithelial to mesenchymal transition on t cell targeting of melanoma cells

Frontiers in Oncology

Volumn 4, Issue DEC, 2014, Pages

  Woods, Katherine ^a,b   Pasam, Anupama ^a,b   Jayachandran, Aparna ^a,b   Andrews, Miles C ^a,b   Cebon, Jonathan ^a,b  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b LA TROBE UNIVERSITY   (Australia)

Author keywords

Cancer testis antigens; Epithelial mesenchymal transition; Melanoma; T cell killing; T lymphocytes; Tumor antigens

Indexed keywords

GENOMIC DNA; TUMOR ANTIGEN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DNA MICROARRAY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOTHERAPY; MELANOMA CELL; MOLECULAR CLONING; MOLECULAR RECOGNITION; PHENOTYPE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; UPREGULATION;

EID: 84922552212     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00367     Document Type: Article

References (30)

1. Hoek KS, Eichhoff OM, Schlegel NC, Dobbeling U, Kobert N, Schaerer L, et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res (2008) 68:650-6. doi:10.1158/0008-5472.CAN-07-2491
2. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 119:1420-8. doi:10.1172/JCI39104
3. Alonso SR, Tracey L, Ortiz P, Perez-Gomez B, Palacios J, Pollan M, et al. A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res (2007) 67:3450-60. doi:10.1158/0008-5472.CAN-06-3481
4. Dissanayake SK, Wade M, Johnson CE, O'Connell MP, Leotlela PD, French AD, et al. The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem (2007) 282:17259-71. doi:10.1074/jbc.M700075200
5. Wehbe M, Soudja SM, Mas A, Chasson L, Guinamard R, De Tenbossche CP, et al. Epithelial-mesenchymal-transition-like and TGFbeta pathways associated with autochthonous inflammatory melanoma development in mice. PLoS One (2012) 7:e49419. doi:10.1371/journal.pone.0049419
6. Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaz D, et al. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov (2013) 3:158-67. doi:10.1158/2159-8290.CD-12-0386
7. Behren A, Anaka M, Lo PH, Vella LJ, Davis ID, Catimel J, et al. The Ludwig institute for cancer research Melbourne melanoma cell line panel. Pigment Cell Melanoma Res (2013) 26:597-600. doi:10.1111/pcmr.12097
8. Jayachandran A, Anaka M, Prithviraj P, Hudson C, Mckeown SJ, Lo PH, et al. Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma. Oncotarget (2014) 5:5782-97.
9. Ribas A, Weber JS, Chmielowski B, Comin-Anduix B, Lu D, Douek M, et al. Intra-lymph node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trial. Clin Cancer Res (2011) 17:2987-96. doi:10.1158/1078-0432.CCR-10-3272
10. Filipazzi P, Pilla L, Mariani L, Patuzzo R, Castelli C, Camisaschi C, et al. Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides. Clin Cancer Res (2012) 18:6485-96. doi:10.1158/1078-0432.CCR-12-1516
11. Tarhini AA, Leng S, Moschos SJ, Yin Y, Sander C, Lin Y, et al. Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. J Immunother (2012) 35:359-66. doi:10.1097/CJI.0b013e31825481fe
12. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer (2005) 5:615-25. doi:10.1038/nrc1669
13. Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, et al. Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A (2008) 105:20422-7. doi:10.1073/pnas.0810777105
14. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun (2004) 4:1.
15. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 10:909-15. doi:10.1038/nm1100
16. Almanzar G, Olkhanud PB, Bodogai M, Dell'Agnola C, Baatar D, Hewitt SM, et al. Sperm-derived SPANX-B is a clinically relevant tumor antigen that is expressed in human tumors and readily recognized by human CD4+ and CD8+ T cells. Clin Cancer Res (2009) 15:1954-63. doi:10.1158/1078-0432.CCR-08-1290
17. Westbrook VA, Schoppee PD, Diekman AB, Klotz KL, Allietta M, Hogan KT, et al. Genomic organization, incidence, and localization of the SPAN-x family of cancer-testis antigens in melanoma tumors and cell lines. Clin Cancer Res (2004) 10:101-12. doi:10.1158/1078-0432.CCR-0647-3
18. Yilmaz-Ozcan S, Sade A, Kucukkaraduman B, Kaygusuz Y, Senses KM, Banerjee S, et al. Epigenetic mechanisms underlying the dynamic expression of cancer-testis genes, PAGE2, -2B and SPANX-B, during mesenchymal-to-epithelial transition. PLoS One (2014) 9:e107905. doi:10.1371/journal.pone.0107905
19. Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature (2012) 490:412-6. doi:10.1038/nature11538
20. Scheel C, Weinberg RA. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol (2012) 22:396-403. doi:10.1016/j.semcancer.2012.04.001
21. Bedi U, Mishra VK, Wasilewski D, Scheel C, Johnsen SA. Epigenetic plasticity: a central regulator of epithelial-to-mesenchymal transition in cancer. Oncotarget (2014) 5:2016-29.
22. Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann KM, Speicher D, et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell (2013) 23:811-25. doi:10.1016/j.ccr.2013.05.003
23. Moustakas A, Heldin P. TGFbeta and matrix-regulated epithelial to mesenchymal transition. Biochim Biophys Acta (2014) 1840:2621-34. doi:10.1016/j.bbagen.2014.02.004
24. Anaka M, Freyer C, Gedye C, Caballero O, Davis ID, Behren A, et al. Stem cell media culture of melanoma results in the induction of a nonrepresentative neural expression profile. Stem Cells (2012) 30:336-43. doi:10.1002/stem.786
25. Zuber P, Kuppner MC, De Tribolet N. Transforming growth factor-beta 2 down-regulates HLA-DR antigen expression on human malignant glioma cells. Eur J Immunol (1988) 18:1623-6. doi:10.1002/eji.1830181023
26. McDermott D, Lebbe C, Hodi FS, Maio M, Weber JS, Wolchok JD, et al. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev (2014) 40:1056-64. doi:10.1016/j.ctrv.2014.06.012
27. Wolchok JD, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K, et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol (2013) 24:2174-80. doi:10.1093/annonc/mdt161
28. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, Mcdermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 366:2443-54. doi:10.1056/NEJMoa1200690
29. Boisgerault N, Kottke T, Pulido J, Thompson J, Diaz RM, Rommelfanger-Konkol D, et al. Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse. Mol Ther (2013) 21:1507-16. doi:10.1038/mt.2013.116
30. Radvanyi L. Immunotherapy exposes cancer stem cell resistance and a new synthetic lethality. Mol Ther (2013) 21:1472-4. doi:10.1038/mt.2013.160